-1753359733653.webp&w=3840&q=75)
2025 NOSCM | HER2 Positive Breast Cancer: Individualizing Treatment to Biology and Response
Overview
Dr. Mark Pegram discussed the DESTINY-Breast09 trial, showing superior PFS with tucatinib plus pertuzumab.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Mark Pegram, MD
Date of Release
July 24th, 2025
-1756043706259.webp&w=3840&q=75)
-1756043607111.webp&w=3840&q=75)